Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $107.33

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given a consensus rating of “Hold” by the twenty-three brokerages that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $107.3333.

A number of research analysts have issued reports on ZBH shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. Barclays reduced their price objective on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a report on Wednesday, November 5th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a report on Wednesday, November 5th. Finally, Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $94.00 to $120.00 in a research note on Monday, January 5th.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $87.42 on Thursday. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The stock has a 50 day simple moving average of $91.59 and a 200-day simple moving average of $96.48. The company has a market cap of $17.32 billion, a price-to-earnings ratio of 21.64, a price-to-earnings-growth ratio of 2.23 and a beta of 0.62. Zimmer Biomet has a 12-month low of $85.33 and a 12-month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.Zimmer Biomet’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is 23.76%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Uncommon Cents Investing LLC increased its position in Zimmer Biomet by 19.2% during the 4th quarter. Uncommon Cents Investing LLC now owns 24,948 shares of the medical equipment provider’s stock worth $2,243,000 after purchasing an additional 4,020 shares in the last quarter. Lodestone Wealth Management LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth about $82,000. Mn Services Vermogensbeheer B.V. raised its position in shares of Zimmer Biomet by 0.9% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 76,244 shares of the medical equipment provider’s stock valued at $6,856,000 after buying an additional 644 shares during the last quarter. Eastern Bank lifted its stake in shares of Zimmer Biomet by 4.5% during the fourth quarter. Eastern Bank now owns 3,740 shares of the medical equipment provider’s stock valued at $336,000 after buying an additional 160 shares during the period. Finally, Dakota Wealth Management boosted its position in Zimmer Biomet by 12.8% during the fourth quarter. Dakota Wealth Management now owns 11,831 shares of the medical equipment provider’s stock worth $1,064,000 after acquiring an additional 1,342 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.